Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - A KIMS database analysis

Nicholas A. Tritos, Amir Hamrahian, Donna King, Susan L. Greenspan, David M. Cook, Peter J. Jönsson, Maria Koltowska-Häggstrom, Beverly M.K. Biller

Research output: Contribution to journalArticle

Abstract

Objective Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH naïve adults. Design and measurements This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Patients A total of 231 GH naive adults were identified (115 women and 116 men) who had BMD measured on the same densitometer in the lumbar spine (LS) and/or femoral neck (FN) both at baseline and after 4 years of GH replacement. Results After 4 years, there was a median (10th, 90th percentile) 4·6% (-5·2%, 12·2%) increase in LS BMD over baseline (P = 0·0001). There was a positive correlation between per cent change in LS BMD and age at the onset of pituitary disease (r = 0·25, P = 0·001). There was no change in FN BMD over baseline [0·0% (-7·3%, 8·5%)]. On multivariate analysis, older age at the onset of pituitary disease predicted a greater increase in LS BMD on GH replacement (r = 0·55, P < 0·0001). Conclusions In a population of GH naïve adults, GH replacement led to a significant increase in LS BMD over baseline, but no change in FN BMD. The potential for greater BMD improvement on GH replacement therapy in adults with disease of later onset should be considered when making treatment decisions in this patient population.

Original languageEnglish (US)
Pages (from-to)178-184
Number of pages7
JournalClinical Endocrinology
Volume79
Issue number2
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Bone Density
Growth Hormone
Databases
Spine
Femur Neck
Pituitary Diseases
Age of Onset
Population Growth
Hormone Replacement Therapy
Decision Making
Multivariate Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - A KIMS database analysis. / Tritos, Nicholas A.; Hamrahian, Amir; King, Donna; Greenspan, Susan L.; Cook, David M.; Jönsson, Peter J.; Koltowska-Häggstrom, Maria; Biller, Beverly M.K.

In: Clinical Endocrinology, Vol. 79, No. 2, 01.08.2013, p. 178-184.

Research output: Contribution to journalArticle

Tritos, Nicholas A. ; Hamrahian, Amir ; King, Donna ; Greenspan, Susan L. ; Cook, David M. ; Jönsson, Peter J. ; Koltowska-Häggstrom, Maria ; Biller, Beverly M.K. / Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - A KIMS database analysis. In: Clinical Endocrinology. 2013 ; Vol. 79, No. 2. pp. 178-184.
@article{bec08e167ff04f79bdca35ae02016552,
title = "Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - A KIMS database analysis",
abstract = "Objective Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH na{\"i}ve adults. Design and measurements This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Patients A total of 231 GH naive adults were identified (115 women and 116 men) who had BMD measured on the same densitometer in the lumbar spine (LS) and/or femoral neck (FN) both at baseline and after 4 years of GH replacement. Results After 4 years, there was a median (10th, 90th percentile) 4·6{\%} (-5·2{\%}, 12·2{\%}) increase in LS BMD over baseline (P = 0·0001). There was a positive correlation between per cent change in LS BMD and age at the onset of pituitary disease (r = 0·25, P = 0·001). There was no change in FN BMD over baseline [0·0{\%} (-7·3{\%}, 8·5{\%})]. On multivariate analysis, older age at the onset of pituitary disease predicted a greater increase in LS BMD on GH replacement (r = 0·55, P < 0·0001). Conclusions In a population of GH na{\"i}ve adults, GH replacement led to a significant increase in LS BMD over baseline, but no change in FN BMD. The potential for greater BMD improvement on GH replacement therapy in adults with disease of later onset should be considered when making treatment decisions in this patient population.",
author = "Tritos, {Nicholas A.} and Amir Hamrahian and Donna King and Greenspan, {Susan L.} and Cook, {David M.} and J{\"o}nsson, {Peter J.} and Maria Koltowska-H{\"a}ggstrom and Biller, {Beverly M.K.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1111/cen.12132",
language = "English (US)",
volume = "79",
pages = "178--184",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - A KIMS database analysis

AU - Tritos, Nicholas A.

AU - Hamrahian, Amir

AU - King, Donna

AU - Greenspan, Susan L.

AU - Cook, David M.

AU - Jönsson, Peter J.

AU - Koltowska-Häggstrom, Maria

AU - Biller, Beverly M.K.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Objective Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH naïve adults. Design and measurements This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Patients A total of 231 GH naive adults were identified (115 women and 116 men) who had BMD measured on the same densitometer in the lumbar spine (LS) and/or femoral neck (FN) both at baseline and after 4 years of GH replacement. Results After 4 years, there was a median (10th, 90th percentile) 4·6% (-5·2%, 12·2%) increase in LS BMD over baseline (P = 0·0001). There was a positive correlation between per cent change in LS BMD and age at the onset of pituitary disease (r = 0·25, P = 0·001). There was no change in FN BMD over baseline [0·0% (-7·3%, 8·5%)]. On multivariate analysis, older age at the onset of pituitary disease predicted a greater increase in LS BMD on GH replacement (r = 0·55, P < 0·0001). Conclusions In a population of GH naïve adults, GH replacement led to a significant increase in LS BMD over baseline, but no change in FN BMD. The potential for greater BMD improvement on GH replacement therapy in adults with disease of later onset should be considered when making treatment decisions in this patient population.

AB - Objective Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH naïve adults. Design and measurements This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Patients A total of 231 GH naive adults were identified (115 women and 116 men) who had BMD measured on the same densitometer in the lumbar spine (LS) and/or femoral neck (FN) both at baseline and after 4 years of GH replacement. Results After 4 years, there was a median (10th, 90th percentile) 4·6% (-5·2%, 12·2%) increase in LS BMD over baseline (P = 0·0001). There was a positive correlation between per cent change in LS BMD and age at the onset of pituitary disease (r = 0·25, P = 0·001). There was no change in FN BMD over baseline [0·0% (-7·3%, 8·5%)]. On multivariate analysis, older age at the onset of pituitary disease predicted a greater increase in LS BMD on GH replacement (r = 0·55, P < 0·0001). Conclusions In a population of GH naïve adults, GH replacement led to a significant increase in LS BMD over baseline, but no change in FN BMD. The potential for greater BMD improvement on GH replacement therapy in adults with disease of later onset should be considered when making treatment decisions in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84880053846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880053846&partnerID=8YFLogxK

U2 - 10.1111/cen.12132

DO - 10.1111/cen.12132

M3 - Article

C2 - 23278636

AN - SCOPUS:84880053846

VL - 79

SP - 178

EP - 184

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -